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Different biological aspects have to be considered when estimating 
the effect of radiotherapy on oligometastases: 
1) In contrast to current systemic treatments, radiotherapy has a high 
potential to inactivate cancer stem cells that are able to cause tu-
mour recurrences. In limited disease stages or, in some cancers, 
limited metastases stages, this is the basis of the curative potential of 
radiotherapy and also of complete inactivation of macroscopic metas-
tases. 
2) Size of the metastases is predictive for in-field-control. This corre-
lation exists in primary tumours as well as in metastases and reflects 
the impact of the higher number of cancer stem cells to be inacti-
vated in larger tumours and maybe also higher impact of other resis-
tance factors like hypoxia. 
3) Metastases develop through vascular spread of tumour cells, i.e. 
oligometastases always bear a high risk of later development of 
further metastases. The time to further disease Progression appears to 
be longest with a longer time interval between treatment of the 
primary tumour and development of oligometastases. While this is 
known for a long time, approaches to biologically characterize tu-
mours with low versus high potential for multi- or oligometastatic 
spread are only recently developed. 
4) Single or oligometastases are often treated using hypofractionated-
accelerated radiation treatment schedules, i.e. applying high doses 
per fraction and higher doses per week as compared to conventionally 
fractionated radiotherapy schedules. These schedules lead to a higher 
biological efficacy in the tumour, but also in irradiated normal organs. 
Thus, for application of high radiation doses, from biological reasons 
the use of high precision radiotherapy techniques is mandatory to take 
advantage from the volume-effects in normal tissues that can com-
pensate for the disadvantage of the high doses per fraction. 
The talk will give an overview on biological considerations for high-
dose radiotherapy of oligometastases and on open questions for 
further improvement of treatment. 
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Two models of circulating tumor cell (CTC) dynamics have been 
proposed to explain the phenomenon of tumor ’self-seeding’, whereby 
CTCs repopulate the primary tumor and accelerate growth: Primary 
Seeding, where cells from a primary tumor shed into the vasculature 
and return back to the primary themselves; and Secondary Seeding, 
where cells from the primary first colonize a secondary tissue which 
then sheds cells into the vasculature returning to the primary. The-
setwo models are difficult to distinguish experimentally, yet the 
differences between them is of great importance to both our under-
standing of the metastatic process and also for designing methods of 
intervention. Therefore we developed a mathematical model to test 
the relative likelihood of these two phenomena and show that Sec-
ondary Seeding is several orders of magnitude more likely than Prima-
ry seeding. We suggest how this difference could effect tumor evolu-
tion, progression and therapy and several possible methods of experi-
mental validation.  
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The role of positron emission tomography (PET) in radiation oncology 
continues to expand beyond the realm of preliminary diagnosis, where 
FDG PET has directly impacted disease staging in more than 30 % of 
cancer patients. Radiation oncology clinicians and researchers seek to 
incorporate PET more objectively into radiotherapy (RT) planning and 
therapeutic response assessment by leveraging its high sensitivity, 
tracer specificity, and capacity for absolute quantification. As PET 
evolves from a qualitative diagnostic tool to a quantitative theragnos-
tic tool, a growing number of clinical trials are evaluating the efficacy 
of personalized and adaptive RT regimens based on the spatiotempor-
al dynamics of heterogeneous PET uptake. 
However, complex quantitative tasks require the estimation and 
mitigation of many PET uncertainties. They arise from physical, 
technical, and biological factors that impact PET lesion signal (con-
trast) relative to noise, system spatial resolution,and reproducibility. 
This talk will review uncertainties that determine confidence intervals 
within which we can trust PET in the context of RT target definition 
and RT response assessment. In particular, physical uncertainties 
arising from the image formation process, technical uncertainties 
from pre- and post-imaging processes, and biological uncertainties 
from patient-specific tracer kinetics and therapy-induced dynamics 
will be presented. 
The level of trust in PET can be linked to the incorporation of uncer-
tainties into quantification processes. For example, test-retest studies 
can establish achievable degrees of precision when assessing longitu-
dinal changes in PET metrics. While some uncertainties are mitigated 
through standardization of imaging procedures within and between 
institutions, others pose formidable challenges that require innovative 
technologies and methodologies. Such challenges motivate the need 
for improved PET quantification and seamless integration into RT 
planning through multidisciplinary collaboration. 
 
  
Example workflow of PET quantification tasks in radiation oncolo-
gy. From tumor biology at the cellular scale to PET-based target 
definition and therapy response assessment at the image voxel scale, 
quantitative tasks carry uncertainties that must be estimated and 
mitigated. This talk will focus on uncertainties in Steps 1 and 2 in the 
context of their impact on downstream components.  
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PET is a functional and molecular imaging modality allowing to meas-
ure (biological) tumor characteristics quantitatively. The most com-
monly used parameter to quantify tumor tracer uptake is the so-called 
maximum standardized uptake value (SUVmax). Yet, various other 
parameters may be of interest. Metabolically active tumor volume 
(MATV), total tumor burden (sum of MATV over all lesions) or total 
lesion glycolysis (TLG, product of MATV and SUV) have shown value as 
predictive or prognostic factor. Beyond measuring glucose consump-
tion with 18F-FDG there is increased interest in the use of other trac-
ers and/or labeled drugs. Proliferation measured with 18F-FLT or 
hypoxia measured with e.g. 18F-AZA can be of particular interest in a 
radiotherapy setting. Specific imaging procedure optimizations may be 
required when using non-FDG PET tracers. In addition, use of simpli-
fied (static) image procedures and data analysis methods may need to 
be validated against full kinetic analysis to determine use of e.g. SUV 
as appropriate surrogate for the physiological parameter of interest. 
Full kinetic analysis can then be helpful to determine which simplified 
quantitative measure is providing the most accurate and robust 
results. For example, tumor to blood ratios may be more suitable than 
SUV measures and SUV normalized by body weight may be suboptimal 
compared to other normalizations, such as body surface area, depend-
ing on the biodistribution of the tracer. 
All quantitative PET measures, however, depend largely on the way 
PET images are collected, reconstructed and analyzed. Moreover, new 
image reconstruction technologies, that include resolution recovery, 
can improved image resolution and contrast recovery, but at the same 
time suffer from increased upward bias when PET images are quanti-
fied using the maximum standardized uptake value. Consequently, 
when implementing new PET imaging technologies one should also 
adapt data analysis procedures in order to obtain and maintain robust 
quantitative data. 
When quantitative PET studies are performed as part of multicenter 
studies it is not only essential to optimize the PET imaging and data 
analysis procedure for the specific question to be addressed, but also 
to make sure that studies are performed in a standardized manner and 
that all scanner performances are harmonized to a common standard. 
There are various organizations that offer scanner validation or accre-
ditation (QC) programs. Most of these programs recognize the need 
not only to verify the basic calibration and uniformity of the PET 
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images but also underline the need for harmonizing image resolution 
and data analysis methodology to ensure harmonized quantitative 
performance across multiple sites.  
This lecture will focus on the impact and interplay of image resolu-
tion, noise and data collection and analysis methodology on the 
various ways of PET tracer uptake quantification. Moreover, the 
impact of relatively new PET technologies, such as time of flight 
technology and new image reconstruction algorithm, on the accuracy 
and precision of tracer uptake quantification will be addressed. 
Finally, based on the first results obtained from the EARL accredita-
tion program, the feasibility and need for a central QA/QC accredita-
tion program will be discussed. 
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The role of positron emission tomography (PET) scanning in radiation 
oncology has evolved as it is the most specific and sensitive means of 
imaging fundamental aspects of tumour biology.  
PET has been applied in different RT procedures: correct staging and 
optimal treatment strategy, accurate delineation of biological target 
volume (BTV) for treatment planning, prediction of  tumor response, 
evaluation of  healthy tissue function after radiotherapy. 
In the era of high-precision radiotherapy, accurate tumor volume 
delineation regarding tumor boundaries, shape and volume is crucial. 
Quite different approaches have been used for target volume delinea-
tion on PET images: the anatomic sites of the pathologic zones on  
PET scan were delineated on CT scan, absolute/relative thresholding 
algorithms, complex algorithms (i.e. gradient/statistical based me-
thods). 
The introduction of the combined PET/CT imaging modalities into 
routine clinical RT practice has promise to be of great clinical signific-
ance in the accurate delineation of RT target volume in the treatment 
of cervix, head and neck, and lung cancers.  
The overall sensitivity, specificity and accuracy of FDG-PET for detec-
tion of lung cancers are very high for primary, residual and recurrent 
disease; contour guided by FDG-PET/CT led to significant modification 
of treatment strategy and radiotherapy planning in NSCLC patients. A 
limiting factor to the accuracy of target volume definition by PET/CT 
is organ and tumor motion, which is mainly due to the patient respira-
tion. Motion management is thus becoming an important issue in both 
diagnostic and RT applications, particularly when PET/CT images are 
used for tumor delineation; within this contest 4D techniques provide 
information which can be used to improve/personalize volume defini-
tion and treatment planning strategy.  
Careful comparison of FDG-PET, MRI and CT scans with the histopa-
thology of resented tumor specimens shows is the most accurate of 
the three for the detection of head and neck cancer.  
PET images are used for tumor detection and delineation, however 
such images may also contain information on the spatial distribution 
of factors influencing tumor radiosensitivity (hypoxia, proliferation) 
and a few studies have used PET in biologic image-guided dose escala-
tion to the radioresistant BTV using IMRT. This use of PET imaging in 
combination with dose escalation is of great interest in tumor sites 
such as head-and-neck and the prostate. 
 
 SYMPOSIUM: DOSIMETRY OF LOW AND MEDIUM 
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Kilovoltage x-rays are something of a Cinderella subject in radiothera-
py physics although accurate absolute dosimetry is perhaps more 
challenging than for megavoltage beams.   
The first step is to determine the energy/quality of the beam.  This is 
usually done in terms of the first half value layer (HVL) measured 
under narrow beam conditions.  In order to fully characterise the 
energy spectrum the generating kV is also needed and TG-61 shows 
that there is wide variation in the HVL for the same generating poten-
tial.  The IAEA defines low energy as up to a generating potential of 
100 kV or 3 mm of Al HVL and medium energy as starting at 80kV or 
2mm of Al.  The IPEM defined an additional very low energy band from 
0.035 mm of Al up to 1 mm (8-50kV) with low energy considered as up 
to 160kV. 
Most standards laboratories offer only an air kerma calibration based 
on ionometry, but PTB also has a calorimetric standard. The IAEA 
TRS398 code of practice offers a formalism for the use of a calibration 
factor defined in terms of absorbed dose to water and suggests that 
standards laboratories that offer only an air kerma calibration could 
also provide calibrations in terms of absorbed dose to water by apply-
ing an appropriate air kerma code of practice.  In IAEA TECDOC1455 
comparing TRS398 to air kerma based codes of practice differences of 
up to 4% were found for low energies but agreement was within 1% for 
medium energies. 
There are two ways in which the output of the machine can then be 
measured: a measurement of air kerma in air together with the 
application of a backscatter factor or a calibration at a relevant depth 
in a phantom.  In the latter case a perturbation correction is needed.  
The magnitude of these corrections is calculated using Monte Carlo 
methods.  Changes to codes of practice of around 7% (at 100kV) have 
been required (IAEA TRS277 and IPEMB revision 2005). The consensus 
seems to be that measurement at 20 mm depth in water is the pre-
ferred approach for medium energy x-rays but codes of practice are 
divided about whether measurements at very low energy (40kV) 
should be in air (e.g. TG61) or a phantom (e.g. IPEMB).  There is 
general agreement that plastic phantoms need to be used with care. 
Newer devices such as the Zeiss Intrabeam device and the Ariane 
Papillon machine use 50kV x-rays with more challenging geometries.  
For these devices special jigs are needed to ensure geometric accura-
cy and GafChromic EBT2 film may also offer an appropriate means of 
reference dosimetry especially for small fields.  For low energies the 
requirement for controlled geometry suggests the use of plastic 
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Purpose/Objective: The Monte Carlo method is the most accurate 
method for radiation measurement simulation and dose calculation. 
This presentation reviews the recent advances of Monte Carlo for low 
and medium energy x-ray beam modeling. 
Material/methods: In the last 20 years significant developments have 
been made in the areas of radiation transport theory, Monte Carlo 
simulation techniques and computer technology, which have enabled 
the Monte Carlo method for widespread applications in radiation 
measurement and clinical radiotherapy dosimetry. Kilovoltage x-rays 
are different from megavoltage x-rays due to their excessive scatter-
ing properties and short electron ranges,which make it possible to 
simulate photon transport only in some Monte Carlo applications such 
as brachytherapy dose calculation.  
Results: We will first start with the Monte Carlo modeling of the air-
filled ionization chamber response in low and medium energy x-ray 
beams where the fractional contributions of the secondary electrons 
from the cavity air and the surrounding chamber media were investi-
gated accurately. This will be followed by Monte Carlo studies of 
ionization chamber corrections factors for the chamber stem and 
waterproofing sheath that demonstrated the accuracy and efficiency 
of Monte Carlo simulations of the photon attenuation and scattering 
effects with the use of correlated sampling techniques. More detailed 
reviews of the Monte Carlo method for radiotherapy dosimetry and 
treatment planning will be given with a focus on radiation source 
modeling, kilovoltage CT dose calculation, and treatment planning 
dose calculation for external beam therapy and brachytherapy.   
Conclusion: The Monte Carlo method has been demonstrated as a 
useful simulation tool for accurate dosimetry measurement and 
radiotherapy dose calculation. 
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X-ray beams with peak energies ranging from around 50 to 300 kilo-
volts were in widespread use until the end of the 1950s when Cobalt 
60 gamma rays and accelerator produced megavoltage x rays took 
over due to their much greater penetrating power. However, almost 
all of our knowledge of (cellular) radiobiology has been derived from 
irradiating cells with kilovoltage x ray sources, for reasons of cost and 
practicability. It is therefore essential that we do not forget about 
their radiobiological properties, even if such radiation qualities play 
only a minor role in today's radiotherapy. Furthermore, the differenc-
es in cell killing between kilovoltage and megavoltage photons (and 
electrons) per unit dose have a great deal to teach us about the 
fundamental mechanisms of the biological effect of radiation. 
